Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus DECADRON LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus DECADRON LA.
DECADRON W/ XYLOCAINE vs DECADRON-LA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
Local anesthesia for surgical proceduresInflammation and pain management in musculoskeletal conditionsOphthalmic conditions (e.g., conjunctivitis, keratitis)Off-label: epidural injection for radicular pain
Allergic statesDermatologic diseasesEndocrine disordersGastrointestinal diseasesHematologic disordersNeoplastic diseasesNervous system disordersOphthalmic diseasesRenal diseasesRespiratory diseasesRheumatic disordersSystemic lupus erythematosusTuberculous meningitis with subarachnoid block or impending block
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site.
Dexamethasone is primarily metabolized by CYP3A4. Lidocaine is extensively metabolized by CYP1A2 and CYP3A4 to active metabolites (MEGX, GX).
Primarily hepatic, via CYP3A4.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%).
Dexamethasone: 77%, primarily albumin. Lidocaine: 60-80%, alpha-1-acid glycoprotein.
Dexamethasone is approximately 77% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG).
Dexamethasone: 0.8-1.0 L/kg (distributes widely). Lidocaine: 1.1-1.6 L/kg (increased in hepatic disease).
Vd for dexamethasone is approximately 0.8-1.0 L/kg (mean ~0.9 L/kg), indicating distribution into total body water.
Dexamethasone: Oral: 80-90%; IM: 100%. Lidocaine: Oral: <35% (first-pass); Epidural: 100%.
Oral: 80-90% (dexamethasone base). Intramuscular: 100% (assuming absorption from depot). Intravenous: 100%.
Dexamethasone: No adjustment. Lidocaine: GFR <10 mL/min: reduce dose by 25-50% or avoid continuous infusion; monitor for toxicity.
No specific dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, consider reducing dose by 25-50% due to prolonged half-life.
Dexamethasone: No adjustment. Lidocaine: Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 75%.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Reduce dose by 75% or use alternative with shorter half-life.
Dexamethasone: 0.08-0.3 mg/kg/day oral/IV divided every 6-12h (max 16 mg/day). Lidocaine: 1-1.5 mg/kg IV bolus (max 100 mg), then 20-50 mcg/kg/min IV infusion; or local infiltration 4.5 mg/kg (max 300 mg) with epinephrine.
0.02-0.3 mg/kg/dose intramuscularly every 1-3 weeks; not to exceed 8 mg as initial dose; titrate based on response.
Dexamethasone: Start at lowest adult dose; monitor for fluid retention and hyperglycemia. Lidocaine: Reduce bolus dose (e.g., 0.5-1 mg/kg) and infusion rate (e.g., 1-2 mg/min); monitor for neurotoxicity and cardiac depression.
Initiate at lower end of dosing range (8 mg intramuscularly) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression; monitor bone density and blood glucose.
Not for intravenous or spinal administration. Lidocaine formulations containing preservatives (e.g., methylparaben) are contraindicated for epidural or intrathecal use due to risk of neurotoxicity.
No FDA boxed warning.
Avoid inadvertent intravascular injection (may cause cardiac arrest). Use caution in patients with hepatic impairment, severe hypertension, or diabetes. Prolonged use may lead to adrenal suppression, Cushing's syndrome, or osteoporosis.
["May cause immunosuppression and increase susceptibility to infections.","Adrenal suppression with prolonged therapy; taper gradually.","Exacerbation of systemic fungal infections; do not use in active fungal infections unless specific antifungal therapy is administered.","Withdrawal symptoms including adrenal insufficiency, fever, myalgia, arthralgia, and malaise.","Kaposi sarcoma has been reported; discontinuation may result in clinical remission.","Avoid live vaccines in patients receiving immunosuppressive doses.","Monitor blood pressure, blood glucose, and electrolytes during prolonged therapy."]
Systemic fungal infections, hypersensitivity to corticosteroids or lidocaine/amide-type anesthetics, severe hypotension, heart block, or concurrent use of class I antiarrhythmics.
["Systemic fungal infections","Hypersensitivity to dexamethasone or any component of the formulation"]
Data Pending Review
Data Pending Review
No significant food interactions. However, dexamethasone may increase appetite and cause fluid retention; patients with hypertension or heart failure should limit sodium intake. Grapefruit juice may increase dexamethasone levels slightly, but not clinically relevant with single injection.
Avoid excessive consumption of salt and potassium-rich foods if on high-dose or long-term therapy. Grapefruit juice may increase systemic exposure to dexamethasone; monitor for increased adverse effects.
First trimester: Increased risk of orofacial clefts (odds ratio 1.3-3.3) with systemic corticosteroids. Second/third trimesters: Possible fetal adrenal suppression, intrauterine growth restriction, and premature rupture of membranes. Lidocaine crosses placenta but not teratogenic at clinical doses.
First trimester: Increased risk of cleft palate (odds ratio 3.35) and cardiovascular defects. Second/third trimester: Fetal adrenal suppression, IUGR, oligohydramnios. Chronic use increases risk of preterm birth.
Dexamethasone: Excreted in breast milk; M/P ratio unknown. Lidocaine: M/P ratio 0.4-0.6, minimal infant exposure. Use caution with high-dose or prolonged therapy. Monitor infant for adrenal suppression (dexamethasone) or CNS effects (lidocaine).
Enters breast milk; M/P ratio 0.25–0.5. Low doses (prednisone ≤20 mg/day) generally compatible. High doses may cause neonatal adrenal suppression. Monitor infant for growth and adrenal function.
Dexamethasone: Increased clearance in pregnancy may require higher doses (e.g., 1.5-2x non-pregnant dose) for adrenal suppression conditions. Lidocaine: Reduced plasma protein binding in pregnancy may increase free fraction; no dose adjustment typically needed for local anesthesia.
Increased clearance due to pregnancy-associated hepatic enzyme induction. May require dose increase. Titrate to lowest effective dose; taper slowly postpartum.
Category C
Category C
Dexamethasone and lidocaine combination for injectable use. Dexamethasone is a potent, long-acting corticosteroid with minimal mineralocorticoid activity; lidocaine provides local anesthesia. Onset of analgesic effect from lidocaine is immediate (1-2 minutes), lasting 1-2 hours; anti-inflammatory effect from dexamethasone begins within hours and lasts days. Do not inject into infected or unstable joints. Avoid intra-articular injection if joint instability or septic arthritis is suspected. Use with caution in patients with bleeding diathesis or on anticoagulants. Maximum single dose of lidocaine with epinephrine is 7 mg/kg; without epinephrine, 4.5 mg/kg. Dexamethasone may cause tendon rupture with repeated injections. Not for intravenous or epidural use. Contraindicated in systemic fungal infections and in patients with known hypersensitivity to components.
Decadron-LA (dexamethasone acetate) is a long-acting injectable corticosteroid. It should be administered deep IM or intra-articularly; not for IV use. Onset is 24-48 hours with duration up to 2-3 weeks. Use caution in patients with diabetes as it can cause hyperglycemia. Avoid use in systemic fungal infections or during an active infection without concurrent antimicrobials.
This medication is a combination of a corticosteroid and a local anesthetic, used to reduce inflammation and provide immediate pain relief when injected into a joint or soft tissue.You may experience temporary pain or swelling at the injection site; apply ice if needed.Avoid strenuous activity or overuse of the injected joint for at least 48 hours to allow the medication to work and prevent injury.Contact your doctor if you have signs of infection: increasing pain, redness, warmth, or fever.Do not receive live vaccines while on this treatment; report any infections or illness to your doctor.Tell your doctor if you have diabetes, as dexamethasone may increase blood sugar levels.This injection is for local use only; do not use it for self-medication or repeated injections without medical advice.
This medication is a long-acting steroid injection; full effects may take a few days to appear.Report any signs of infection (fever, redness, swelling) or sudden mood changes to your healthcare provider.Do not receive live vaccines while on this medication.If you have diabetes, monitor your blood glucose more closely as this drug can raise blood sugar.Inform all healthcare providers that you have received this injection, especially before any surgery.